Oestrogen and nigrostriatal dopaminergic neurodegeneration: Animal models and clinical reports of parkinson's disease

Clinical and Experimental Pharmacology and Physiology

Volumn 34, Issue 7, 2007, Pages 555-565

  Liu, Bin ^a,b   Dluzen, Dean E ^a  

^a Northeastern Ohio Medical University   (United States)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Dopamine; Neurodegeneration; Oestrogen; Parkinson's disease

Indexed keywords

CAFFEINE; CONJUGATED ESTROGEN; DOPAMINE; DOPAMINE TRANSPORTER; ESTRADIOL; ESTRADIOL BENZOATE; ESTROGEN; LEVODOPA; MOXESTROL; NEUROLEPTIC AGENT; NEUROTOXIN;

CLINICAL TRIAL; DEMENTIA; DEPRESSION; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; DYSTONIA; ESTRUS CYCLE; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; LOW DRUG DOSE; MENOPAUSAL SYNDROME; MOTOR DYSFUNCTION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; SHORT SURVEY; SLEEP DISORDER; STRIATONIGRAL DEGENERATION;

ANIMALS; BASAL GANGLIA; DISEASE MODELS, ANIMAL; DOPAMINE; ESTROGENS; HUMANS; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PARKINSONIAN DISORDERS; SUBSTANTIA NIGRA;

EID: 34250711184     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04616.x     Document Type: Short Survey

References (71)

1. Dluzen DE, Disshon KA, McDermott JL. Estrogen as a modulator of striatal dopaminergic neurotoxicity. In: Marwah J, Teitelbaum H (eds). Advances in Neurodegenerative Disorders, Vol. 1: Parkinson's Disease. Prominent Press, Scottsdale, AZ. 1998 149 92.
2. Lichtensteiger W. Cyclic variations of catecholamine content in hypothalamic nerve cells during the estrous cycle of the rat, with a concomitant study of the substantia nigra. J. Pharmacol. Exp. Ther. 1969 165 : 204 15.
3. Shughrue PJ. Estrogen attenuates the MPTP-induced loss of dopamine neurons from the mouse SNc despite a lack of estrogen receptors (ERalpha and ERbeta). Exp. Neurol. 2004 190 : 468 77.
4. D'Astous M, Gajjar TM, Dluzen DE, Di Paolo T. Dopamine transporter as a marker of neuroprotection in methamphetamine-lesioned mice treated acutely with estradiol. Neuroendocrinology 2004 79 : 296 304.
5. Arvin M, Fedorkova L, Disshon KA, Dluzen DE, Leipheimer RE. Estrogen modulates responses of striatal dopamine neurons to MPP(+): Evaluations using in vitro and in vivo techniques. Brain Res. 2000 872 : 160 71.
6. Disshon KA, Dluzen DE. Estrogen as a neuromodulator of MPTP-induced neurotoxicity: Effects upon striatal dopamine release. Brain Res. 1997 764 : 9 16.
7. Disshon KA, Dluzen DE. Estrogen reduces acute striatal dopamine responses in vivo to the neurotoxin MPP+ in female, but not male rats. Brain Res. 2000 868 : 95 104.
8. Dluzen D. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine. Brain Res. 1997 767 : 340 4.
9. Murray HE, Pillai AV, McArthur SR et al. Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: Differential actions of estrogen in males and females. Neuroscience 2003 116 : 213 22.
10. DeGiorgio LA, Attardi B, Shimizu Y, Ogata M, Volpe BT. 17Beta-estradiol treatment retards excitotoxic delayed degeneration in substantia nigra reticulata neurons. Brain Res. 2002 936 : 15 20.
11. Ramirez AD, Liu X, Menniti FS. Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice. Neuroendocrinology 2003 77 : 223 31.
12. Dluzen DE, McDermott JL, Anderson LI. Tamoxifen diminishes methamphetamine-induced striatal dopamine depletion in intact female and male mice. J. Neuroendocrinol. 2001 13 : 618 24.
13. Callier S, Morissette M, Grandbois M, Di Paolo T. Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice. Synapse 2000 37 : 245 51.
14. D'Astous M, Morissette M, Tanguay B, Callier S, Di Paolo T. Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice. Synapse 2003 47 : 10 14.
15. Grandbois M, Morissette M, Callier S, Di Paolo T. Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice. Neuroreport 2000 11 : 343 6.
16. Dluzen DE, McDermott JL, Liu B. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice. Neurotoxicol. Teratol. 1996 18 : 603 6.
17. Dluzen DE, McDermott JL, Liu B. Estrogen alters MPTP-induced neurotoxicity in female mice: Effects on striatal dopamine concentrations and release. J. Neurochem. 1996 66 : 658 66.
18. Dluzen DE, McDermott JL, Anderson LI. Tamoxifen eliminates estrogen's neuroprotective effect upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system. Neurotox. Res. 2001 3 : 291 300.
19. Miller DB, Ali SF, O'Callaghan JP, Laws SC. The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann. N.Y. Acad. Sci. 1998 844 : 153 65.
20. Gao X, Dluzen DE. The effect of testosterone upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Brain Res. 2001 892 : 63 9.
21. Myers RE, Anderson LI, Dluzen DE. Estrogen, but not testosterone, attenuates methamphetamine-evoked dopamine output from superfused striatal tissue of female and male mice. Neuropharmacology 2003 44 : 624 32.
22. Datla KP, Murray HE, Pillai AV, Gillies GE, Dexter DT. Differences in dopaminergic neuroprotective effects of estrogen during estrous cycle. Neuroreport 2003 14 : 47 50.
23. Yu L, Liao PC. Sexual differences and estrous cycle in methamphetamine-induced dopamine and serotonin depletions in the striatum of mice. J. Neural Transm. 2000 107 : 419 27.
24. Gomez-Mancilla B, Bedard PJ. Effect of estrogen and progesterone on l-dopa induced dyskinesia in MPTP-treated monkeys. Neurosci. Lett. 1992 135 : 129 32.
25. Bedard P, Dankova J, Boucher R, Langelier P. Effect of estrogens on apomorphine-induced circling behavior in the rat. Can. J. Physiol. Pharmacol. 1978 56 : 538 41.
26. Bedard PJ, Boucher R, Dankova J, Langelier P. Female sexual hormones influence motor behaviour in rats after lesion of the entopeduncular nucleus. Neurosci. Lett. 1980 17 : 89 94.
27. Bedard P, Boucher R, Di Paolo T, Labrie F. Biphasic effect of estradiol and domperidone on lingual dyskinesia in monkeys. Exp. Neurol. 1983 82 : 172 82.
28. Euvrard C, Oberlander C, Boissier JR. Antidopaminergic effect of estrogens at the striatal level. J. Pharmacol. Exp. Ther. 1980 214 : 179 85.
29. Xu K, Xu Y, Brown-Jermyn D et al. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,3,6-tetrahydropyridine model of Parkinson's disease. J. Neurosci. 2006 : 26 : 535 41.
30. Liu B, Dluzen DE. Effect of estrogen upon methamphetamine-induced neurotoxicity within the impaired nigrostriatal dopaminergic system. Synapse 2006 60 : 354 61.
31. Gajjar TM, Anderson LI, Dluzen DE. Acute effects of estrogen upon methamphetamine induced neurotoxicity of the nigrostriatal dopaminergic system. J. Neural Transm. 2003 110 : 1215 24.
32. Gao X, Dluzen DE. Tamoxifen abolishes estrogen's neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Neuroscience 2001 103 : 385 94.
33. Ferraz AC, Xavier LL, Hernandes S et al. Failure of estrogen to protect the substantia nigra pars compacta of female rats from lesion induced by 6-hydroxydopamine. Brain Res. 2003 986 : 200 5.
34. Yu L, Kuo Y, Cherng CG, Chen HH, Hsu CH. Ovarian hormones do not attenuate methamphetamine-induced dopaminergic neurotoxicity in mice gonadectomized at 4 weeks postpartum. Neuroendocrinology 2002 75 : 282 7.
35. Anderson LI, Leipheimer RE, Dluzen DE. Effects of neonatal and prepubertal hormonal manipulations upon estrogen neuroprotection of the nigrostriatal dopaminergic system within female and male mice. Neuroscience 2005 130 : 369 82.
36. Shulman LM. Is there a connection between estrogen and Parkinson's disease? Parkinsonism Relat. Disord. 2002 8 : 289 95.
37. Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF. Postmenopausal estrogen use affects risk for Parkinson disease. Arch. Neurol. 2004 61 : 886 8.
38. Blanchet PJ, Fang J, Hyland K, Arnold LA, Mouradian MM, Chase TN. Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: A crossover study. Neurology 1999 53 : 91 5.
39. Saunders-Pullman R, Gordon-Elliott J, Parides M, Fahn S, Saunders HR, Bressman S. The effect of estrogen replacement on early Parkinson's disease. Neurology 1999 52 : 1417 21.
40. Dupont A, Di Paolo T, Gagne B, Barden N. Effects of chronic estrogen treatment on dopamine concentrations and turnover in discrete brain nuclei of ovariectomized rats. Neurosci. Lett. 1981 22 : 69 74.
41. Pasqualini C, Olivier V, Guibert B, Frain O, Leviel V. Acute stimulatory effect of estradiol on striatal dopamine synthesis. J. Neurochem. 1995 65 : 1651 7.
42. Tsang KL, Ho SL, Lo SK. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology 2000 54 : 2292 8.
43. Sandyk R. Estrogens and the pathophysiology of Parkinson's disease. Int. J. Neurosci. 1989 45 : 119 22.
44. Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 2003 60 : 790 5.
45. Marder K, Tang MX, Alfaro B et al. Postmenopausal estrogen use and Parkinson's disease with and without dementia. Neurology 1998 50 : 1141 3.
46. Tang MX, Jacobs D, Stern Y et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996 348 : 429 32.
47. Gregoire AJ, Kumar R, Everitt B, Henderson AF, Studd JW. Transdermal oestrogen for treatment of severe postnatal depression. Lancet 1996 347 : 930 3.
48. Popat RA, Van Den Eeden SK, Tanner CM et al. Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology 2005 65 : 383 90.
49. Benedetti MD, Maraganore DM, Bower JH et al. Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: An exploratory case-control study. Mov. Disord. 2001 16 : 830 7.
50. Ragonese P, D'Amelio M, Salemi G et al. Risk of Parkinson disease in women: Effect of reproductive characteristics. Neurology 2004 62 : 2010 14.
51. Quinn NP, Marsden CD. Menstrual-related fluctuations in Parkinson's disease. Mov. Disord. 1986 1 : 85 7.
52. Session DR, Pearlstone MM, Jewelewicz R, Kelly AC. Estrogens and Parkinson's disease. Med. Hypotheses 1994 42 : 280 2.
53. Bedard P, Langelier P, Villeneuve A. Oestrogens and extrapyramidal system. Lancet 1977 ii : 1367 8.
54. Koller WC, Barr A, Biary N. Estrogen treatment of dyskinetic disorders. Neurology 1982 32 : 547 9.
55. Robinson RO, Stutchfield P, Hicks B, Marsden CD. Estrogens and dyskinesia. Neurology 1984 34 : 404 5.
56. Villeneuve A, Langlier P, Bedard P. Estrogens, dopamine and dyskinesias. Can. Psychiatr. Assoc. J. 1978 23 : 68 70.
57. Villeneuve A, Cazejust T, Cote M. Estrogens in tardive dyskinesia in male psychiatric patients. Neuropsychobiology 1980 6 : 145 51.
58. Strijks E, Kremer JA, Horstink MW. Effects of female sex steroids on Parkinson's disease in postmenopausal women. Clin. Neuropharmacol. 1999 22 : 93 7.
59. Kompoliti K, Comella CL, Jaglin JA, Leurgans S, Raman R, Goetz CG. Menstrual-related changes in motoric function in women with Parkinson's disease. Neurology 2000 55 : 1572 5.
60. Dluzen DE, McDermott JL. Estrogen, anti-estrogen, and gender: Differences in methamphetamine neurotoxicity. Ann. N.Y. Acad. Sci. 2002 965 : 136 56.
61. Disshon KA, Dluzen DE. Use of in vitro superfusion to assess the dynamics of striatal dopamine clearance: Influence of estrogen. Brain Res. 1999 842 : 399 407.
62. Thompson TL. Attenuation of dopamine uptake in vivo following priming with estradiol benzoate. Brain Res. 1999 834 : 164 7.
63. Ascherio A, Weisskopf MG, O'Reilly EJ et al. Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: The modifying effects of estrogen. Am. J. Epidemiol. 2004 160 : 977 84.
64. Chen JF, Xu K, Petzer JP et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 2001 21 : RC143 (1 6).
65. Schipper HM. Astrocytes, brain aging, and neurodegeneration. Neurobiol. Aging 1996 17 : 467 80.
66. Jonassen JA, Leeman SE. Developmental and hormonal regulation of the sex difference in preprotachykinin gene expression in rat anterior pituitaries. Ann. N.Y. Acad. Sci. 1991 632 : 1 9.
67. Nikolaus S, Huston JP, Korber B, Thiel C, Schwarting RK. Pretreatment with neurokinin substance P but not with cholecystokinin-8S can alleviate functional deficits of partial nigrostriatal 6-hydroxydopamine lesion. Peptides 1997 18 : 1161 8.
68. Ascherio A, Zhang SM, Hernan MA et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann. Neurol. 2001 50 : 56 63.
69. Benedetti MD, Bower JH, Maraganore DM et al. Smoking, alcohol, and coffee consumption preceding Parkinson's disease: A case-control study. Neurology 2000 55 : 1350 8.
70. Ravina BM, Fagan SC, Hart RG et al. Neuroprotective agents for clinical trials in Parkinson's disease: A systematic assessment. Neurology 2003 60 : 1234 40.
71. Mickley KR, Dluzen DE. Dose-response effects of estrogen and tamoxifen upon methamphetamine-induced behavioral responses and neurotoxicity of the nigrostriatal dopaminergic system in female mice. Neuroendocrinology 2004 79 : 305 16.